The latest ROE for ASMB is -0.01%. That is below the Healthcare sector average of 20.86%. Investors often review this figure alongside Assembly Biosciences's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, ASMB currently prints -0.01% for ROE, while the sector average sits near 20.86%. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Assembly Biosciences's growth, margins, and balance sheet.

Return on Equity shows how effectively Assembly Biosciences converts resources into returns. At -0.01%, ASMB may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ASMB's ROE (-0.01%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Assembly Biosciences's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.